好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ischemic and Hemorrhagic Stroke in Native Americans
Neuro Trauma, Critical Care, and Sports Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
4-011

We aimed to characterize demographic and clinical characteristics of the Native American stroke population and identify predictors of in-patient mortality.

Stroke is a leading cause of morbidity and mortality in the United States. Native Americans constitute 1.5% of the population. Multiple studies have examined how stroke affects minority groups. However, existing data on stroke in Native Americans (NA)remains extremely limited. 

We evaluated claims data from California acute care hospitals between 2005-2011. California has the largest NA population in the US. Using validated ICD-9 codes, we identified primary ischemic (AIS) and hemorrhagic stroke (ICH) admissions and ascertained comorbidities and in-hospital complications.  We compared baseline characteristics across race/ethnic groups and identified independent predictors of hospital mortality using univariate and multivariate logistic regression. 

We identified 283,107  strokes in California between 2005 and 2011. (234,471 AIS [83%] and 48,636 ICH [17%]). Of these, 851 (0.3%) were NA (including AIS 698 [82%] and ICH 153[18%]). For AIS, NA had intermediate prevalence of vascular risk factors, including smoking history (15% vs 18% in Blacks and 11% in Whites, p<0.001) and diabetes (46% vs 48% in Hispanics and 26% in Whites, p<0.001). Native Americans with AIS were least likely to receive palliative care (1% vs 4% in Whites, p<0.001). In ICH, NA had the second highest proportion of chronic kidney disease (13% vs. 17.5% in Blacks and 8.1% in Whites, p<0.001) and the highest proportion of diabetes (41% vs. 37% in Hispanics and 21% in Whites, p<0.001). In-hospital mortality was similar among minorities (4% [AIS], 26%  [ICH], p>0.2). In both AIS and ICH, predictors of in-hospital mortality were similar to other minority groups including atrial fibrillation (p=0.002) in AIS and female sex (p=.005) in ICH. 

Native Americans constitute an important understudied minority population in stroke. NA have high prevalence of modifiable risk factors including diabetes and smoking. 

Authors/Disclosures
Zachary King (Yale)
PRESENTER
No disclosure on file
Rachel Beekman, MD (Yale New Haven Medical Center) Dr. Beekman has nothing to disclose.
Stacy C. Brown, MD (The Queen's Medical Center, Neuroscience Institute) Dr. Brown has nothing to disclose.
Audrey Leasure Ms. Leasure has nothing to disclose.
Hailey A. Orgass, PA (NYP Weill Cornell Medical Center) No disclosure on file
Emily J. Gilmore, MD (Yale University School of Medicine) Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
Lauren H. Sansing, MD Dr. Sansing has nothing to disclose.
Charles Matouk Charles Matouk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Silk Road Medical. Charles Matouk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Charles Matouk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Navigantis.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Guido J. Falcone, MD (Yale School of Medicine) The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.